Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
fda
4
×
life sciences
national blog main
national top stories
roche
boston
boston blog main
boston top stories
clinical trials
deals
genentech
san francisco blog main
san francisco top stories
alexion pharmaceuticals
alnylam pharmaceuticals
avapritinib
billy dunn
biogen
blueprint medicines
boehringer ingelheim
cancer
cancer immunotherapy
center for medicare and medicaid services
companion diagnostic
cstone pharmaceuticals
daniel o'day
dicerna pharamceuticals
drug prices
drug pricing
eli lilly
europe top stories
european medicines agency
evrysdi
fisogatinib
flatiron health
foundation medicine
foundationone cdx
foundationone heme
gene therapy
What
roche
4
×
drug
fda
intended
medicine
medicines
pay
team
acquire
agreed
approval
approved
atrophy
big
billion
blueprint
broad
cancer
candidate
caught
causing
confidence
currently
daily
dicerna
didn’t
disease
evrysdi
eye
foundation
friday
gain
gene
genentech
green
hepatitis
home
lights
liquid
marketing
Language
unset
Current search:
roche
×
biotech
×
fda
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine